A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.

被引：0
|
作者：
Elez, Elena [1 ]
Lenz, Heinz-Josef [2 ]
de Jonge, Maja [3 ]
Yaeger, Rona [4 ]
Doi, Toshihiko [5 ]
Pronk, Linda [6 ]
Teufel, Michael [7 ]
Marzin, Kristell [8 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Erasmus Med Ctr Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Boehringer Ingelheim Espana SA, Clin Dev Oncol, Madrid, Spain
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT514
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors.
    Tolcher, Anthony W.
    Victoria, Ivan
    Germann, Nathalie
    Luecke, Stephan
    Bailey, Mark
    Kordes, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [3] A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, K. P.
    Mendelson, D. S.
    Tolcher, A. W.
    Patnaik, A.
    Burris, H. A.
    Rasco, D. W.
    Bendell, J. C.
    Gordon, M. S.
    Kato, G.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H. H.
    Woo, T.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
    Eskens, F.
    Oldenhuis, C. N.
    Bhargava, P.
    Loos, W.
    Esteves, B.
    van Doorn, L.
    Cotreau, M. M.
    Dhillon, R.
    Gietema, J. A.
    De Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [7] Low-density lipoprotein receptor-related protein 5 (LRP5) polymorphisms in patients with osteoporosis
    Reginato, AM
    Neer, R
    Briggs, C
    Olsen, BR
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 363 - 363
  • [8] Phase 1, open-label, dose-escalation study of M3814 ± avelumab radiotherapy (RT) in patients (pts) with advanced solid tumors.
    Bendell, Johanna C.
    Shafique, Michael Rahman
    Perez, Bradford
    Chennoufi, Sarah
    Beier, Frank
    Trang, Ky
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.
    Puzanov, Igor
    LoRusso, Patricia
    Papadopoulos, Kyriakos P.
    Chen, Christopher T.
    LeBruchec, Yvan
    He, Xiaomin
    Cousin, Thierry
    Havenith, Karin
    Boni, Joseph
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    Investigational New Drugs, 2013, 31 : 409 - 416
12345